1998
A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer
Abstract: Summary A phase trial of the combination of irinotecan (CPT-11) with cisplatin in advanced non-small cell lung cancer (NSCLC) showed a very promising response rate of 54% in previously untreated NSCLC patients. This study was conducted to confirm the activity and toxicities of CPT-11 and cisplatin combination for previously untreated NSCLC in a multi-institutional phase 11 study. Seventy patients with stage IIIB or IV NSCLC received CPT-11 60 mg m-2 intravenously (IV) on days 1, 8 and 15, and cisplatin 80 mg m…
Search citation statements
Paper Sections
Select...
51
12
7
0
Citation Types
2
42
1
0
Year Published
Range
1998
2026
Publication Types
Select...
63
1
Relationship
3
61
Authors
Journals
Cited by 64 publications
(45 citation statements)
References 27 publications
2
42
1
0
Smart CitationsHow the paper below cites the one you are viewing
“…The treatment outcomes of the present study were superior or at least comparable to the results of previous multi-institutional trials of a combination of CPT-11 plus CDDP (Masuda et al, 1998(Masuda et al, , 1999DeVore et al, 1999;Niho et al, 1999). Recently, superiority of 2-drug combinations of one of the newly developed agents, vinorelbine or paclitaxel, with CDDP to the representative CDDP-based chemotherapy in the 1980s such as CDDP plus vindesine or etoposide was reported in prospective randomized trials (Le Chevalier et al, 1994;Bonomi et al, 2000).…”
Section: Discussion
supporting
confidence: 81%
Abstract